Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Higher-Risk Myelodysplastic Syndrome (HR-MDS)”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Early research (Phase 1)Study completedNCT02942290
What this trial is testing

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes (MDS)
AbbVie 134
Early research (Phase 1)Ended earlyNCT05424380
What this trial is testing

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Who this might be right for
Leukemia, Myeloid, Acute
GlaxoSmithKline 18
Testing effectiveness (Phase 2)Study completedNCT03672539
What this trial is testing

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07749976
What this trial is testing

GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

Who this might be right for
Acute Myeloid LeukemiaDiffuse Large B Cell Lymphoma (DLBCL)High Risk Myelodysplastic Syndrome+2 more
Vitruviae 108
Testing effectiveness (Phase 2)Ended earlyNCT03594955
What this trial is testing

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Who this might be right for
Leukaemia
Sanofi 7
Large-scale testing (Phase 3)Not Yet RecruitingNCT06927232
What this trial is testing

AZA+Lus VS AZA Monotherapy in HR-MDS

Who this might be right for
Higher-risk Myelodysplastic Syndrome
Peking Union Medical College Hospital 86
Testing effectiveness (Phase 2)WithdrawnNCT05829434
What this trial is testing

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Neoplasm
Uwe Platzbecker
Large-scale testing (Phase 3)Study completedNCT03268954
What this trial is testing

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Takeda 454
Testing effectiveness (Phase 2)Looking for participantsNCT02115295
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center 508
Large-scale testing (Phase 3)Looking for participantsNCT06641414
What this trial is testing

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Who this might be right for
Higher-risk Myelodysplastic Syndrome
Ascentage Pharma Group Inc. 490
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Testing effectiveness (Phase 2)Looking for participantsNCT07710534
What this trial is testing

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

Who this might be right for
Relapsed / Refractory AMLHigh Risk Myelodysplastic SyndromeHigh Risk Myeloproliferative Neoplasms
Virginia Commonwealth University 40
Not applicableLooking for participantsNCT06439199
What this trial is testing

Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Nantes University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT02610777
What this trial is testing

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Millennium Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Early research (Phase 1)Looking for participantsNCT06501196
What this trial is testing

BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+3 more
BlossomHill Therapeutics 170
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583552
What this trial is testing

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
GCP-Service International West GmbH 46
Early research (Phase 1)Looking for participantsNCT07384715
What this trial is testing

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Who this might be right for
R/R AMLR/R HR-MDSAcute Myeloid Leukemia+1 more
Genmab 78
Testing effectiveness (Phase 2)Study completedNCT00954941
What this trial is testing

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Who this might be right for
Hematologic DiseasesAcute Myelogenous LeukemiaMyelodysplastic Syndrome+1 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Ended earlyNCT05086315
What this trial is testing

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic Syndromes+1 more
Sanofi 101
Next Page